Faculty & Staff Details
|Name:||Sachin Shah, Pharm.D., BCOP, FCCP|
|Position:||Associate Professor, Adult Medicine Division, Dallas VA|
|Bio||Dr. Shah is an Associate Professor of Pharmacy Practice at TTUHSC and a hematology/oncology clinical pharmacist at the VA North Texas Health Care System (VANTHCS). He provides his clinical services to in- and out-patient medical team. He is a program director for ASHP Accredited Hematology/Oncology Specialty Residency at the Dallas/Fort Worth Campus. He provides Inpatient Clinical Skills clerkship to 3rd year pharmacy candidates, and Adult Medicine and elective Oncology clerkships to 4th year pharmacy candidates and pharmacy residents. He serves a chair or Student Affairs Committee.|
Dr. Shah received his Doctor of Pharmacy degree from Texas Tech University HSC – School of Pharmacy and completed his Pharmacy Practice Residency at the Baptist Health System in San Antonio, Texas. Thereafter, he completed specialty residency in Hematology/Oncology at the South Texas Veterans Health Care System, Audie L. Murphy division and the University of Texas HSC, San Antonio. He received his Board Certified Oncology Pharmacist certification in 2003.
Texas Pharmacy License 39235 2000 02/29/08
Texas Preceptor Licensure 2000 02/29/08
Board Certified Oncology Pharmacist 2004 07/03/05
June 2006 Hematology/Oncology Pharmacy Association (HOPA) Clinical Practice Award at 2nd HOPA Annual Meeting, Orlando, FL
April 2006 Lewis S. Smith Pharmacy Practitioner Award at Texas Society of Health-System Pharmacists (TSHP) Annual Seminar, Galveston, TX
May 2006 DFW Campus P3 preceptor of the Year Award for 2005 -2006 – Texas Tech University HSC - School of Pharmacy
April 2004 School-wide P3 Teaching Team of the Year for PHAR 4264 Oncology – Texas Tech University HSC - School of Pharmacy
April 2003 School-wide P3 Teaching Team of the Year for PHAR 4264 Oncology – Texas Tech University HSC - School of Pharmacy
July 2005 Outstanding Research Poster Award – Fourth Annual Research Days at Texas Tech University HSC – School of Pharmacy, Amarillo, TX
August 2005 Guest editor: Practical consideration for the use of IGIV therapy. Am J Health Syst Pharm 2005;62(Suppl 3)
June 1998 Best poster presentation award, “Hepatocyte Growth Factor Induces Tubulogenesis of Primary Renal Proximal Tubular Epithelial Cells”, Merck Undergraduate Research Seminar, Estes Park, Colorado
Dec 1996 First place, Community Action Project, PHAR 1100 on Attention Deficit Disorder at Texas Tech University HSC, Amarillo, Texas
Dr. Shah’s primary research interests include supportive care in cancer, immunoglobulin, targeted therapies, chemotherapy toxicity, lung cancer, colon cancer, and multiple myeloma. He has received Outstanding Research Poster Award at fourth Annual Research Days at TTUHSC – School of Pharmacy. He has served as a guest editor for Am J Health Syst Pharm and published in international journal Drugs.
Dr. Shah is a Hematology/Oncology Clinical Specialist at the VANTHCS in Dallas. He is an active member of hematology/oncology in-patient consult service and out-patient clinic. He also serves on Cancer Task Force and Pain Management Committee at the VANTHCS. Dr. Shah has been recognized at State and National levels for his clinical practice. He has been awarded Lewis S. Smith Pharmacy Practitioner Award at Texas Society of Health System Pharmacists (TSHP) in April 2006. He also has received Hematology/Oncology Pharmacy Association (HOPA) Clinical Practice Award at 2nd HOPA Annual meeting. Dr. Shah serves on Residency Advisory Council and provides ASHP accredited hematology/oncology specialty residency program at VANTHCS.
Dr. Shah has served as a Chair of the Council on Professional Affairs for the Texas Society of Health-System Pharmacists. He was a treasurer to local DFW ACCP chapter. In addition, he provides numerous ACPE approved CE programs at local, state and national level. Dr. Shah has served as a reviewer for Pharmacotherapy, Current Medical Research and Opinion, Journal of Pharmacy Technology, Annals of Pharmacotherapy, Clinical Evidence, American Journal of Kidney Diseases and The Medical Letter.
Shah SR, Walsh TL, Williams CB, et al. Gefitinib (ZD1839, Iressa®): a selective epidermal growth factor receptor-tyrosine kinase inhibitor. J Oncol Pharm Practice 2003;9:151-160
Shah SR, Vervan M. Use of i.v. immune globulin and occurrence of associated acute renal failure and thrombosis. Am J Health-Syst Pharm 2005;62:720-725
Stanford BL, Shah SR, Ballard EE, Jumper CA, Rabinowitz I, Dowell JE, Hunt WC, Kriger JA. A randomized trial assessing the utility of a test dose program with taxanes. Curr Med Res Opin 2005;21:1611-1616.
Shah S. Practical consideration for the use of IGIV therapy: Introduction: Am J Health
Syst Pharm 2005;62(Suppl 3):S3-4.
Shah S. Pharmacy consideration for the use of IGIV therapy. Am J Health Syst Pharm
Villela LR, Stanford BL, Shah SR*. Pemetrexed – A unique anti-folate therapeutic
alternative in oncology. Pharmacotherapy 2006;26:641-654.
Shah S, Dowell J, Greene S. An evaluation of clinical pharmacy services in a
hematology/oncology outpatient setting. Ann Pharm 2006;40:1527-1533.
Shah SR, Tran T. Lenalidomide in Myelodysplastic Syndrome and Multiple Myeloma. Drugs 2007;67:1869-1881.
Hall RG, Shah SR, Villela LR, Amirkhan RH. Impact of indadequate empiric antimicrobial therapy on clinical outcomes of patients with Escherichia coli or Klebsiella species bacteremia. Pharmacy Practice 2007;20:392-398.